CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1996
Prevalence of factor V Leiden in a Canadian blood donor population.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee D H, Henderson P A, Blajchman M A
Аннотация
OBJECTIVE: To determine the prevalence of factor V Leiden in a Canadian blood donor population.
DESIGN: Cross-sectional laboratory study.
SETTING: Hamilton Centre of the Canadian Red Cross Society.
PARTICIPANTS: Volunteer donors who attended Hamilton Centre blood donor clinics over a 4-day period in August 1994; blood samples from 356 people were evaluable.
OUTCOME MEASURES: Presence of factor V Leiden.
RESULTS: Factor V Leiden was detected in 19 of the 356 people, for a prevalence rate of 5.3% (95% confidence interval 3.0% to 7.6%). All 19 people were shown to be heterozygous for the mutation.
CONCLUSION: Factor V Leiden is common in the Canadian population. Its prevalence is similar to that reported in other Western countries. These data are relevant in the clinical management of patients at risk for venous thrombosis and those with recurrent thrombotic disorders.
DESIGN: Cross-sectional laboratory study.
SETTING: Hamilton Centre of the Canadian Red Cross Society.
PARTICIPANTS: Volunteer donors who attended Hamilton Centre blood donor clinics over a 4-day period in August 1994; blood samples from 356 people were evaluable.
OUTCOME MEASURES: Presence of factor V Leiden.
RESULTS: Factor V Leiden was detected in 19 of the 356 people, for a prevalence rate of 5.3% (95% confidence interval 3.0% to 7.6%). All 19 people were shown to be heterozygous for the mutation.
CONCLUSION: Factor V Leiden is common in the Canadian population. Its prevalence is similar to that reported in other Western countries. These data are relevant in the clinical management of patients at risk for venous thrombosis and those with recurrent thrombotic disorders.